SCHEMBL31401372

SCHEMBL31401372

Cc1ccc(Br)[n+]([O-])c1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3626862 1.00
SCHEMBL11956561 0.80 KDM4E (0.38)
SCHEMBL21963307 0.70 TSHR (0.35)
SCHEMBL4546534 0.68
SCHEMBL31168638 0.67 ALDH1A1 (0.30)
SCHEMBL1861724 0.67 ALDH1A1 (0.30)
SCHEMBL943724 0.65
SCHEMBL8248277 0.61 TSHR (0.37)
SCHEMBL11956563 0.59 TSHR (0.39)
Hydrochloric Acid SCHEMBL5953218 0.59 ALDH1A1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed